Source: BMJ 2009;339:b4525
Author: Erich M Sturgis et al.

Excerpt from article:

The article by Kim and Goldie on the cost effectiveness of including boys in a human papillomavirus (HPV) vaccination programme made assumptions about oropharyngeal cancers that are inaccurate.1 The prevalence of HPV in oropharyngeal cancer used in the article (31%) is based on worldwide estimates,2 but its prevalence in the US, where the research was done, is much higher.3 4

Source data for the review article referenced by the authors give the US specific HPV prevalence as 47% (42% for types 16/18),2 5 and other more recent high quality studies from the US have found rates as high as 72%.3 Furthermore, a recent population based study within the Colorado SEER registry found an HPV prevalence rate of 79% for oropharyngeal cancers diagnosed after 1994.4

Authors:
Erich M Sturgis, associate professor1, Kristina R Dahlstrom, doctoral student2

Author affiliations:
1 Department of Head and Neck Surgery and Department of Epidemiology, University of Texas, MD Anderson Cancer Center, Houston, Texas 77030, USA, 2 University of Texas School of Public Health, Houston, Texas, USA